Bill 119 s 1095, also known as the "Sham Citizen Petition Deterrence Act," aims to empower the Federal Trade Commission (FTC) to prevent the misuse of citizen petitions in the pharmaceutical industry. The bill specifically targets the practice of filing sham citizen petitions as a way to delay the approval of generic drugs or biosimilars and stifle competition.
The main goal of the bill is to promote competition in the pharmaceutical market and ensure that legitimate public health concerns are addressed in a timely manner. By deterring the filing of sham citizen petitions, the FTC can facilitate the efficient review of petitions that are filed in good faith and genuinely raise important public health issues.
Overall, Bill 119 s 1095 seeks to protect consumers by preventing anti-competitive practices in the pharmaceutical industry and promoting a fair and transparent review process for citizen petitions. It aims to strike a balance between fostering competition and safeguarding public health concerns.